The leading Migraine Companies such as ​ Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity ...

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

Here is a brief rundown of some coming entertainment options in Northeast Ohio. Make submissions for consideration via email to [email protected] or [email protected]. You ...

CompanyOverview|NASDAQ:VKTX] Viking Therapeutics Inc. (NASDAQ: VKTX) reported earnings after the market closed on Apr. 23.

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound ...

half-life, which Metsera said was at least as good as approved and clinical-stage drugs in the class, which include Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide).

Set before the events of Half-Life 2, Alyx is working to fight off the Combine with her father Eli. It’s a stunning game and incredibly well-done in VR from Valve. Now the question is if we’ll ...

it fits into the series chronologically between Half-Life 1 and 2. You are Alyx Vance, fighting against the Combine alongside her father, Eli. Though fans questioned the decision to develop the ...

and therefore half-life, of its mRNA. Both of these therapies have the potential to cure Dravet. In 85% of cases, this severe form of epilepsy is caused by haploinsufficiency of the SCN1A gene.

Notably, the half-life of amyloid re-accumulation in the brain after treatment ... Donanemab, a recombinant humanized IgG1 monoclonal antibody developed by Eli Lilly, works by specifically recognizing ...